Physician profile
Christopher Le
NPI 1508399577
$24,426.13
in general payments reported to CMS, 2019-2025
46 companies · $5,548 in 2025
The $5,548 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $717 · 2021: $3,565 · 2022: $3,521 · 2023: $5,616 · 2024: $5,459 · 2025: $5,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,379.16 |
| Education | $243.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,452.20 | 2020-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $2,777.40 | 2020-2025 | |
| Genzyme Corporation | $1,998.33 | 2020-2025 | |
| Ucb, INC. | $1,551.23 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,454.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,151.21 | 2021-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $1,134.46 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Mallinckrodt Hospital Products INC. | $1,100.57 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $890.49 | 2020-2025 | Ofev, Cyltezo, Spevigo |
| Novartis Pharmaceuticals Corporation | $849.15 | 2022-2025 | |
| Lilly USA, LLC | $820.70 | 2020-2025 | Taltz, Kisunla, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $813.94 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $788.93 | 2020-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $777.63 | 2023-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $533.84 | 2020-2025 | Tymlos |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.